Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12774146 | 0.91 | GAA (0.32) | — | |
| SCHEMBL14079926 | 0.88 | NPSR1 (0.34) | — | |
| SCHEMBL14079925 | 0.88 | NPSR1 (0.31) | — | |
| SCHEMBL10519854 | 0.87 | — | — | |
| SCHEMBL29329020 | 0.86 | NPSR1 (0.37) | — | |
| SCHEMBL14079927 | 0.86 | NPSR1 (0.37) | — | |
| SCHEMBL14079928 | 0.86 | NPSR1 (0.37) | — | |
| SCHEMBL14079934 | 0.82 | KDM4E (0.35) | — | |
| SCHEMBL2084825 | 0.82 | PHGDH (0.32) | — | |
| SCHEMBL19293363 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| US-8129366-B2 | VLA-4 inhibitory drug | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
| US-20080200433-A1 | Molecular Chaperone Function Regulator | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-08-21 | — | — | US | disclosed |
| US-20080200433-A1 | Molecular Chaperone Function Regulator | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-08-21 | — | — | US | disclosed |
| US-20070265260-A1 | Quinazoline derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-11-15 | — | — | US | disclosed |
| US-20070265260-A1 | Quinazoline derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-11-15 | — | — | US | disclosed |
| US-7294629-B2 | Quinazoline derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-13 | — | — | US | disclosed |
| US-7294629-B2 | Quinazoline derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | EGFR, ERBB2, ERBB4 | CYP1A2 3174/4885TDP1 2827/4885 |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | CYP1A2 1039/4885TDP1 4867/4885 |
| US-20070265260-A1 | Quinazoline derivatives | TYK2, ROR1, JAK1 | CYP1A2 2781/4885TDP1 1537/4885 |
| US-20080200433-A1 | Molecular Chaperone Function Regulator | HSPBP1, HSF1, HSPH1 | CYP1A2 4023/4885TDP1 2597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.